15.00-15.10
Combination of MRI-based parameters with MR/US-fusion targeted
biopsy-proven risk-factors may improve staging of prostate cancer. T.
Matsugasumi E. Baco, E. Suen, J. C. Bernhard, R. Azhar, A. L. de
Castro Abreu, I. S. Gill, O. Ukimura (Los Angeles, USA; Oslo, N)
15.13-15.23
The role of early repeated biopsies with MRI-ultrasound fusion system
in the selection process of patients eligible for Active Surveillance
after a first TRUS-guided 12 biopsies scheme. A single-center
prospective study. E. Potiron, J. Lacoste, T. Rousseau, G. lLe Goguic,
G. Aillet, P. Nevoux (Nantes, F)
15.26-15.36
Innovations in prostate biopsy strategies for active surveillance and
focal therapy. K. Mammen (Ludhiana, India)
15.39-15.49
Novel 3D-mapping biopsy techniques (including both re-visiting
to target the previous positive trajectory and systematic field biopsy to
target the previously negative field for cancer) for active surveillance
and focal therapy. O. Ukimura (Los Angeles, USA)
15.52-16.02
Incidence of organ-confined prostate cancer with unilateral pattern
of Gleason <= 3 + 4 suitable for focal therapy
F. Bertolotto, F. Germinale , M. Raggio, P. Puppo (Genoa, Imperia, I)
16.05-16.15
Shear wave elastography for localization of prostate cancer lesions
and assessment of elasticity thresholds: Implications for targeted
biopsies and active surveillance protocols. L.Budaeus (Hamburg , D)
16.18-16.28
Role of multiparametric magnetic resonance imaging (MRI) in focal
therapy for prostate cancer. F. Cornud (Paris, F)
16.31-16.41 Focal HIFU treatment of localized prostate cancer diagnosed and
controlled with MRI-ultrasound fusion targeted biopsies : preliminary
results. E. Potiron, J. Lacoste, T. Rousseau, G. Le Goguic, G. Aillet, P.
Nevoux (Saint Herblain, Nantes, F)
16.44-16.54
Real-time transrectal ultrasonography-guided hands-free technique for
focal cryoablation of the prostate. O. Ukimura (Los Angeles, USA)
17. 00-17.30 Panel discussion: no more AS or focal therapy with “old fashioned” biopsy?
17.30
Closing remarks
Faculty
E. Baco (Oslo, N) • F. Bertolotto, (Imperia, I) • B. Beyer (Hamburg,D) • L.Budaeus
(Hamburg , D) • F. Cornud (Paris, F) • A. Fandella (Monastier di Treviso, I)
• M. Ferriero (Rome, I) • R. Galli (Modena, I) • A. Giacobbe (Turin, I) •
B. A. Hadaschik (Heidelberg, D) • B. Malavaud (Toulouse, F) • K. Mammen
(Ludhiana, India) • S. McRae (Houston, USA) • P. Mozer (Paris, F.) • V. Panebianco
(Rome, I) • J. M. Pina (Lisbon, P) • S. Polanec ( Wien, A) • E. Potiron (Nantes,
F) • P. Puppo (Genoa, I) • V. Scattoni (Milan, I) • T. Shin (Yufu-shi, Oita, J) • G.
Simone (Turin, I) S. Takahata (Tokyo, J) • O. Ukimura (Los Angeles, USA)
CONFERENCE VENUE
HOTEL MELIÁ ROMA AURELIA ANTICA
Via degli Aldobrandeschi, 223 – 00163 Roma
Tel. + 39 06 665441
E-mail: [email protected]
www.melia.com
ORGANIZING SECRETARIAT
SINTHESIS S.r.l.
Via S.M.G. Rossello, 24
17027 Pietra Ligure (SV)
Tel./Fax +39 019 626485
E-mail [email protected]
LANGUAGE
The official language of the conference is English. No simultaneous translation will be provided.
REGISTRATION INFO
Written requests via fax or email must be sent to the Organizing Secretariat in order to register
for the Conference together with the copy of the registration fee payment.
Upon receipt of the registration and the required payment, a written confirmation and an invoice
will be sent by e-mail. The numbers for the conference are limited; registrations will be accepted
within and not later than 10 January 2015 on first come, first served basis therefore on site
registrations will not be guaranteed.
Registrations not accompanied by the relevant payment will not be accepted.
Registration fee (VAT 22% included)
Euro 244,00 (not applicable for published work presenters)
The registration fee includes: admission to scientific sessions, lunch & coffee break, delegate’s
bag, certificate of attendance.
Registration fees must be paid only in Euro (€) by the following methods:
- Bank transfer to Sinthesis S.r.l.
Cassa di Risparmio di Savona S.p.A.
IBAN IT31S0631049320000000781080
SWIFT CODE CRSVIT2S117
reason: registration Consensus Biopsy Rome 2015
Important: all bank charges are to be borne
by the transmitter.
- Cheque made out to: Sinthesis S.r.l. to be sent to:
Sinthesis S.r.l., Via S.M.G. Rossello, 24 – 17027
Pietra Ligure (SV).
CERTIFICATE OF ATTENDANCE
The certificate of attendance will be issued to all registered participants on request at the
Organizing Secretariat desk after h. 10.00 a.m. on 24 January 2015.
24
3
2
y
r
Janua
aly
t
I
me
Ro
International challenge conference
on MRI and biopsy in the diagnosis of
prostate cancer
Scientific Chairman
HOW TO REACH
CONFERENCE VENUE
The Melià Roma Aurelia
Antica Hotel, is located
just minutes from the Via
Aurelia and the Ring Road
(exit Aurelia-Vatican City)
in a green and quiet area,
not far from the Fiumicino
Airport (22 km), from
Ciampino Airport (26 km),
from the Termini railway
station (11 km) and a few
kilometers from Piazza San
Pietro, Castel Sant’Angelo
and the Vatican Museums.
Paradigm shift
in prostate
cancer diagnosis:
how new standards
arise from imagebased technologies
P. Puppo (Genoa, I)
Vatican city
Hotel Melia Roma
Aurelia antica
Fiumicino Airport
Termini railway
station
Colosseo
Ciampino Airport
Scientific Board
E. Baco (Oslo, N)
L. Budaeus (Hamburg, D)
F. Cornud (Paris, F)
M. Gallucci (Rome, I)
B. Malavaud (Toulouse, F)
P. Mozer (Paris, F)
V. Panebianco (Rome, I)
O. Ukimura (Los Angeles, USA)
Scientific Secretariat
F. Bertolotto (Imperia, I)
A. Fandella (Monastier di Treviso, I)
M. Ferriero (Rome, I)
Program
18.30-19.15 KEYNOTE LECTURES
09.55 – 10.10 Discussion: fusion, transperineal
Chairmen: L. Budaeus, M.Gallucci
10.10 -10.30
Coffee break
12 ‘ + 3’ discussion
18.30-18.45
Indications for MRI and biopsy under dutasteride treatment.
A. Fandella (Monastier di Treviso, I)
10.30 -10.40
MRI-ultrasound fusion targeted biopsies (KOELIS). A Single-center
prospective study. E. Potiron, P. Nevoux, T. Rousseau, G. Le Goguic,
G. Aillet, J. Lacoste (Nantes, F)
14.30-16.00 PROSTATE MAPPING WITH OR WITHOUT TRACKING: FROM
FICTION TO FACT ?
Chairmen: B. Malavaud, P. Mozer
18.45-19.00
Infective complications after standard TRUS and MRI/TRUS image
fusion guided targeted prostate biopsies. Fewer biopsy cores may not
mean fewer infections. E. Baco (Oslo, N)
10.40-10.50
3D US versus US/MRI fusion-guided target biopsy to detect
prostate cancer: a preliminary experience. M. Ferriero, G. Simone, R.
Papalia, S. Guaglianone, M. Gallucci (Rome, I)
14.30-14.45 Maximum performance of conventional and saturation prostate
mapping V. Scattoni (Milan, I)
19.00-19.15 Lymph node metastases in prostate cancer patients – Size, extension
and implications for radiological imaging based on 6804 lymph nodes.
B. Beyer, C. Meyer, S. R. Leyh Bannurah, G. Salomon, M. Graefen, L.
Budaeus (Hamburg, D)
10.50 -11.00
Ultrasound/MRI fusion vs. systematic 12-core prostate rebiopsy:
preliminary experience. A. Giacobbe, G. Simone, D. Collura,
E. Castelli, R. Rosso, G. L. Muto, L. D’Urso, G. Muto. (Turin, I)
y 23
nuar
a
J
,
y
a
Frid
14.00 Welcome and Introduction - P. Puppo
14.45-15.00
Detection rate in a French series of prostate mapping. B. Malavaud
15.00-15.15
The correspondence between conventional and 3D controlled mapping.
P. Mozer (Paris, F)
15.15-15.30
Detection rate of stereotactic prostate mapping with needle tracking
and virtual simulator
F. Bertolotto, P. Puppo, M. Raggio, F. Germinale (Genoa, Imperia, I)
(Toulouse, F)
15.30-15.45 2D-US versus 3D-US guided saturation biopsy to detect prostate
cancer. M. Ferriero, G. Simone, R. Papalia, R. Mastroianni,
S. Guaglianone, M. Gallucci (Rome, I)
15.45-16.00Discussion
16.00-16.30 panel: Are we still allowed to perform prostate
mapping without 3D tracking system?
16.30-17.00
Coffee break
17.00-18.30THE VALUE OF MULTIPARAMETRIC MRI IN THE WORK-UP
OF PROSTATE CANCER DIAGNOSIS
Chairmen: F. Cornud, V. Panebianco
17.00-17.20 Actual performances of 1.5 and 3 tesla MRI in the diagnosis of prostate
cancer. V. Panebianco (Rome, I)
17.20-17.35
MRI visualization of the anterior part of the prostate. E. Baco (Oslo, N)
17.35 -17.45 The use of MRI prior prostate biopsy in a tertiary care centre: A plea for
standardization. B. Beyer, S. R. Leyh Bannurah, H. Heinzer, A. Haese,
M. Graefen, L. Budaeus (Hamburg, D)
17.45-18.00
The Pirads system. F. Cornud (Paris, F)
18.00-18.10
Clinical significance of the absence of MRI target
F. Bertolotto, P. Puppo (Imperia, Genoa, I)
18.10-18.30 Discussion
a
uary
y, Jan
Saturd
24
08.30–12.40 BIOPSY AFTER MRI : COGNITIVE , FUSION, IN BORE
TARGETING
Chairmen: E. Baco, F. Cornud
08.30-08.40
Comparing cognitive fusion with randomized prostate biopsies. The
value of Multiparametric Prostatic MRI in the detection of cancer. J.
M. Pina, J. L. Dias, L. Campos Pinheiro (Lisbon, P)
08,40-08.50
Multiparametric MRI followed by targeted prostate biopsy for men at second
biopsy: a clinical decision analysis. A. Fandella (Monastier di Treviso, I)
08-50-09.00
Discussion: Cognitive
09.00 -09.10 Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion
Guided. K. Mammen (Ludhiana, India)
09.10-09.25
MRI-targeted fusion biopsies:
transperineal approach. B. A. Hadaschik (Heidelberg, D)
09.25-09.35
Clinical application of targeted stereotactic prostate biopsy:
preliminary experience in our center. R. Galli, E. Martorana, A.
Zordani, A. Ghaith, M Paterlini, S. Micali, G. Bianchi (Modena, I)
09.35-09.45
New biopsy method of prostate using fusion guided imaging, MRI and
real-time TRUS images. S. Takahata , Y. Wakumoto, A. Tsujumura,
S. Hisasue, D. Nozaki, F. Shimizu, K. Terai, H. Aoki, S. Shiozawa,
T. China, T. Ieda, T. Ashizawa, N. Nagaya, Y. Aoki, S. Horie (Tokyo, J)
09.45-09.55 Initial experience of transperineal targeted prostate biopsy using real
time magnetic resonance imaging (MRI) and transrectal ultrasound
(TRUS) image fusion. T. Shin, H. Fujinami, T. Narimatsu, F. Sato, H.
Mimata (Yufu-shi, Oita, J)
11.00 -11.10 Diagnostic performance of multiparametric MRI in prostate cancer:
per core analysis of two prospective ultrasound/MRI fusion biopsy
datasets. G. Simone, A. Giacobbe, D. Collura, R. Papalia, S.
Guaglianone, G. L. Muto, M. Gallucci, G. Muto, M. Ferriero. (Turin, Rome, I)
11.10 -11.25
Discussion: Fusion, transrectal
11.25-11.35 Detection of significant prostate cancer with MR-targeted biopsies:
Should TRUS-MRI fusion guided biopsies alone be a standard of
care? N. B. Delongchamps. A. Lefèvre, N. Bouazza, F. Beuvon, P.
Legman, F. Cornud (Paris, F)
11.35-11.45
Sensitivity, specificity, PPV / NPV of MRI “target” with targeted
“fusion biopsy”
F. Bertolotto, F. Germinale, M. Raggio, P. Puppo (Genoa, Imperia, I)
11.45-12.00
Discussion: MRI targeted only?
12.00 -12.10
Magnetic resonance imaging-guided prostate biopsy in a patients
cohort with previous suspicous MRI to rule out Prostate cancer.
S. Polanec , K. Pinker, M. Susani, P. Brader, T. Helbich, P. Baltzer ( Wien, A)
12.10-12.25
Transgluteal in-bore MR guided prostate biopsy for patients with
transrectal ultrasound (TRUS) biopsy findings that are discordant with
PSA level. S. Sabir, S. McRae, K. Ahrar, H. Choi, J. Ward - (Houston, USA)
12.25 -12.40
Discussion: in bore
12.40-14.00
Work lunch
14.00-15.00 Panel: DO WE NEED NEW GUIDELINES FOR PROSTATE BIOPSY?
Chairman: A. Fandella
Panelists: B. Malavaud, P. Mozer, B. Hadaschik
15.00-17.00 THE IDEAL BIOPSY FOR ACTIVE SURVEILLANCE AND
FOCAL THERAPY
Chairmen: P. Puppo, O. Ukimura
3 ‘ discussion after each lecture